Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy

Clinical Nephrology

Volumn 83, Issue 1, 2015, Pages 57-60

  Giaime, Philippe ^a   Daniel, Laurent ^b   Burtey, Stéphane ^b  

^a Clinique Bouchard   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

C3 glomerulopathy; Dense deposit disease; Membranoproliferative glomerulonephritis; Rituximab

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NEPHRITIC FACTOR; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; BLOOD PRESSURE; C3 GLOMERULOPATHY; CASE REPORT; CAUCASIAN; COMPLEMENT ALTERNATIVE PATHWAY; CREATININE BLOOD LEVEL; DENSE DEPOSIT DISEASE; DRUG TOLERANCE; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; HYPOPROTEINEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; LIPODYSTROPHY; MALE; MALIGNANT HYPERTENSION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NEPHRITIS; PROTEINURIA; REMISSION; BIOPSY; FACE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; GLOMERULUS; PATHOLOGY;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOPSY; FACE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; MALE; REMISSION INDUCTION;

EID: 84921640578     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107945     Document Type: Article

References (13)

1. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis-a new look at an old entity. N Engl J Med. 2012; 366: 1119-1131.
2. Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. 2012; 81: 434-441.
3. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, Smoyer W, Tully HF, Tully SP, Walker P, Welsh M, Würzner R, Zipfel PF. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol. 2005; 16: 1392-1403.
4. Radhakrishnan S, Lunn A, Kirschfink M, Thorner P, Hebert D, Langlois V, Pluthero F, Licht C. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med. 2012; 366: 1165-1166.
5. McCaughan JA, O'Rourke DM, Courtney AE. E. Recurrent membranoproliferative glomerulonephritis after second renal graft treated with plasmapheresis and rituximab. Am J Transplant. 2012; 12: 1046-1051.
6. Kattah AG, Fervenza FC. Rituximab: emerging treatment strategies of immune-mediated glomerular disease. Expert Rev Clin Immunol. 2012; 8: 413-421.
7. Kong WY, Swaminathan R, Irish A. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int Urol Nephrol. 2012; 45: 795-802.
8. Sugiura H, Takei T, Itabashi M, Tsukada M, Moriyama T, Kojima C, Shiohira T, Shimizu A, Tsuruta Y, Amemiya N, Ogawa T, Uchida K, Tsuchiya K, Nitta K. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract. 2011; 117: c98-c105.
9. Smith RJ, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, de Córdoba SR, Hageman GS, Jokiranta TS, Kimberling WJ, Lambris JD, Lanning LD, Levidiotis V, Licht C, Lutz HU, Meri S, Pickering MC, Quigg RJ, Rops AL, Salant DJ, Sethi S, Thurman JM, Tully HF, Tully SP, van der Vlag J, Walker PD, Würzner R, Zipfel PF; Dense Deposit Disease Focus Group. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007; 18: 2447-2456.
10. Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med. 2012; 366: 1161-1163.
11. Chauvet C. American Society of Nephrology, San Diego Nov 2012, Abstract TH-PO445.
12. Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012; 7: 748-756.
13. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011; 3: 85ra46.